

October 12, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai: 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub: Statement of Investor Complaints

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended September 30, 2022:

Sr. No	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	01
2	No. of Investor Complaints received during the quarter	00
3	No. of Investor Complaints disposed off during the quarter	01
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	00

Please take the same on records.

Yours faithfully,

For Glenmark Life Sciences Ltd.



Rudolf Corriea
Company Secretary & Compliance Officer

